Hemostatic powder for gastrointestinal malignant tumor bleeding
Clinical Endoscopy · 25.03.2026
DOI: 10.5946/ce.2025.387 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Endoscopy, online erschienen am 25.03.2026. Verfasst von Thanrada Vimonsuntirungsri und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok….
Abstract (Originalsprache)
Gastrointestinal (GI) tumor bleeding remains a major clinical challenge worldwide, particularly for endoscopists. GI malignant tumor bleeding is uniquely characterized by diffuse oozing and friable tissue, which is vulnerable to further injury. This poses inherent limitations to conventional endoscopic treatments, resulting in low immediate hemostasis rates and a high risk of rebleeding. Traditional salvage surgery or embolization is the rescue treatment; however, they carry a higher mortality risk in the absence of stabilization. Importantly, survival in these patients depends on definitive oncological therapy, and endoscopic hemostasis is an essential frontline approach as a critical bridge to subsequent tumor treatment. Over the past decade, hemostatic powder has evolved into a promising treatment for malignant GI bleeding, distinguished by its ability to provide broad mucosal coverage through non-contact application. To date, adequately powered randomized controlled trials and meta-analyses have demonstrated superior immediate hemostasis and lower rebleeding rates with only a hemostatic powder agent (TC-325) over conventional endoscopic therapy. Thus, the efficacy of other hemostatic powder agents needs to be explored. To date, no luminal or systemic adverse events have been reported in studies on malignant bleeding, reassuring the safety of hemostatic powder in this setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Zitieren
APA
Vimonsuntirungsri, T., & Pittayanon, R. (2026). Hemostatic powder for gastrointestinal malignant tumor bleeding. Clinical Endoscopy. https://doi.org/10.5946/ce.2025.387
Vancouver
Vimonsuntirungsri T, Pittayanon R. Hemostatic powder for gastrointestinal malignant tumor bleeding. Clinical Endoscopy. 2026. doi:10.5946/ce.2025.387
BibTeX
@article{Vimonsuntirungsri2026,
author = {Vimonsuntirungsri, Thanrada and Pittayanon, Rapat},
title = {Hemostatic powder for gastrointestinal malignant tumor bleeding},
journal = {Clinical Endoscopy},
year = {2026},
doi = {10.5946/ce.2025.387}
}
EUVIMED